The Exceptional Responders Initiative: Welcoming More Cases

The initiative is studying tissue, clinical, and genomic data from patients with cancer who have had dramatic and long-lasting responses...

Who Will Respond to PD-1 Inhibition? Study Provides Clues

A new study shows that specific DNA changes in a tumor may help determine which patients are most likely to...

Scope Of Cfp In India

According to a recent report, there will be a need for 50,000 CFPs in India in the next few years....

FDA Approves First Therapy for High-Risk Neuroblastoma

The FDA has approved dinutuximab as part of first-line therapy for children with high-risk neuroblastoma. Source link

Making Sense of Key Cancer Reports

Several regularly released reports, including the Annual Report to the Nation—which is jointly released by NCI and several other organizations—provide...

A Week of Excitement and Hope: Communicating the Story of Cancer

Peter Garrett, acting director of NCI’s communications office, discusses the Annual Report to the Nation on the Status of Cancer...

Looking to the Future of Childhood Cancer Research

NCI’s Dr. Malcolm Smith discusses future directions of childhood cancer research, including treatment directions and clinical trials. Source link

The Importance of Cancer Prevention Research and its Challenges

Barry Kramer, M.D., M.P.H., talks about NCI’s efforts for improving cancer prevention and early detection, two topics discussed in the...

A Message to the Cancer Research Community

Doug Lowy, M.D., a long-time researcher and leader at NCI, greats the cancer research community as the institute’s new acting...